Avalo Therapeutics (NASDAQ:AVTX) Raised to “Hold” at Wall Street Zen

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other research analysts have also recently commented on AVTX. Guggenheim assumed coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $40.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. HC Wainwright increased their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Finally, Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $13.89 on Friday. The company has a market capitalization of $316.55 million, a P/E ratio of -2.42 and a beta of 0.84. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The business’s 50 day simple moving average is $15.47 and its 200 day simple moving average is $15.81.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million. On average, sell-side analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.03% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Large investors have recently bought and sold shares of the business. PFS Partners LLC increased its position in Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after purchasing an additional 1,000 shares in the last quarter. BIT Capital GmbH bought a new position in Avalo Therapeutics in the 3rd quarter valued at approximately $25,000. Geode Capital Management LLC boosted its position in Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after buying an additional 2,648 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in Avalo Therapeutics in the second quarter valued at approximately $55,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics during the third quarter worth $143,000. 87.06% of the stock is owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.